-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Type 2 diabetes mellitus (T2DM) is common in individuals with atherosclerotic cardiovascular disease (ASCVD) and increases the risk of
morbidity and mortality.
Ideally, treatment decisions for these patients are determined by the potential risk of cardiovascular complications in the
patient.
Purpose: In this study, our aim was to develop a model that predicts the mid-term ASCVD events in trials using siagliptin (TECOS) to assess cardiovascular outcomes in individuals with both T2DM and ASCVD, and to externally validate the findings
of ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial participants.
Methods: Using sitagliptin (TECOS) to evaluate data from cardiovascular outcome trials, we used a Cox proportional risk model to predict MACE in patients with T2DM and ASCVD
.
Results: Overall, 1491 (10.
Table 1 uses the multivariate of the extended risk score to adjust the model output parameters
Figure 1 Prediction and 4-year incidence of major cardiovascular adverse events (MACEs) based on simplified and extended risk scores for predicted risk decimal digits
.
Table 2 uses the variables in the delicacy risk score to adjust the model output parameters using the variables
Figure 2 Cumulative incidence of MACE in the quintiles of risk scores in the A Derivation (TECOS) and B Validation (ACCORD) cohorts
.
Conclusion: In patients with T2DM and ASCVD, this 9-factor risk model can quantify the risk of complications of future ASCVD and inform treatment and intensity decisions
.
Stevens SR, Segar MW, Pandey A, Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.